NASDAQ:LRMR

Larimar Therapeutics Stock Forecast, Price & News

$11.33
-0.09 (-0.79 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.20
Now: $11.33
$12.08
50-Day Range
$11.42
MA: $16.31
$18.23
52-Week Range
$8.64
Now: $11.33
$25.87
Volume61,215 shs
Average Volume69,424 shs
Market Capitalization$174.12 million
P/E RatioN/A
Dividend YieldN/A
Beta0.65
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LRMR
CUSIPN/A
CIKN/A
Phone844 511 9056
Employees28
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$17.22 per share

Profitability

Net Income$-45,410,000.00

Miscellaneous

Market Cap$174.12 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

412th out of 2,025 stocks

Pharmaceutical Preparations Industry

198th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$11.33
-0.09 (-0.79 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LRMR News and Ratings via Email

Sign-up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Larimar Therapeutics (NASDAQ:LRMR) Frequently Asked Questions

Is Larimar Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Larimar Therapeutics stock.
View analyst ratings for Larimar Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Larimar Therapeutics?

Wall Street analysts have given Larimar Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Larimar Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Larimar Therapeutics' next earnings date?

Larimar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Larimar Therapeutics
.

How were Larimar Therapeutics' earnings last quarter?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) issued its quarterly earnings results on Wednesday, March, 3rd. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by $0.19.
View Larimar Therapeutics' earnings history
.

What price target have analysts set for LRMR?

2 brokers have issued twelve-month price objectives for Larimar Therapeutics' shares. Their forecasts range from $29.00 to $29.00. On average, they expect Larimar Therapeutics' stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 156.0% from the stock's current price.
View analysts' price targets for Larimar Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Larimar Therapeutics' key executives?

Larimar Therapeutics' management team includes the following people:
  • Dr. Carole S. Ben-Maimon, CEO, Pres & Director (Age 62)
  • Mr. Michael Celano, Chief Financial Officer (Age 62)
  • Mr. John Berman, VP of Fin. & Operations
  • Ms. Jennifer Spokes Johansson, VP of Regulatory Affairs & Counsel
  • Dr. Nancy M. Ruiz, Chief Medical Officer
  • Mr. Francis Michael Conway, VP & Controller

Who are some of Larimar Therapeutics' key competitors?

What is Larimar Therapeutics' stock symbol?

Larimar Therapeutics trades on the NASDAQ under the ticker symbol "LRMR."

How do I buy shares of Larimar Therapeutics?

Shares of LRMR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Larimar Therapeutics' stock price today?

One share of LRMR stock can currently be purchased for approximately $11.33.

How much money does Larimar Therapeutics make?

Larimar Therapeutics has a market capitalization of $174.12 million.

How many employees does Larimar Therapeutics have?

Larimar Therapeutics employs 28 workers across the globe.

What is Larimar Therapeutics' official website?

The official website for Larimar Therapeutics is larimartx.com.

Where are Larimar Therapeutics' headquarters?

Larimar Therapeutics is headquartered at THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004.

How can I contact Larimar Therapeutics?

Larimar Therapeutics' mailing address is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. The company can be reached via phone at 844 511 9056 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.